The evolving use of arsenic in pharmacotherapy of malignant disease
For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, gen...
Gespeichert in:
Veröffentlicht in: | Annals of hematology 2013-06, Vol.92 (6), p.719-730 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 730 |
---|---|
container_issue | 6 |
container_start_page | 719 |
container_title | Annals of hematology |
container_volume | 92 |
creator | Kritharis, Athena Bradley, Thomas P. Budman, Daniel R. |
description | For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy. |
doi_str_mv | 10.1007/s00277-013-1707-3 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1357185552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2984714861</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</originalsourceid><addsrcrecordid>eNp1kMlOwzAQhi0EoqXwAFxQJM6G8ZLYOaKKTarEpZwtJ560qZoFu6nUt8dVCuLCXOYw_6L5CLll8MAA1GMA4EpRYIIyBYqKMzJlUnAKqZbnZAq5yGkaZ0KuQtgAMK4lvyQTLmQuOYgpmS_XmOC-2-7rdpUMAZOuSqwP2NZlUrdJv7a-sWW3W6O3_eF4bey2XrW23SWuDmgDXpOLym4D3pz2jHy-PC_nb3Tx8fo-f1rQUgq9o6muFGdSVzLFIuNcWFfkZaHzUrmsAGszcOByXoLDQrGKZ1rLVGpbca1QOjEj92Nu77uvAcPObLrBt7HSMJEqpuOnPKrYqCp9F4LHyvS-bqw_GAbmiM2M2EzEZo7YjIieu1PyUDTofh0_nKKAj4IQT-0K_Z_qf1O_AbWLdzE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1357185552</pqid></control><display><type>article</type><title>The evolving use of arsenic in pharmacotherapy of malignant disease</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kritharis, Athena ; Bradley, Thomas P. ; Budman, Daniel R.</creator><creatorcontrib>Kritharis, Athena ; Bradley, Thomas P. ; Budman, Daniel R.</creatorcontrib><description>For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-013-1707-3</identifier><identifier>PMID: 23494203</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Antineoplastic Agents - adverse effects ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Arsenic Poisoning - diagnosis ; Arsenic Poisoning - etiology ; Arsenicals - administration & dosage ; Arsenicals - adverse effects ; Arsenicals - pharmacology ; Arsenicals - therapeutic use ; Biotransformation - genetics ; Biotransformation - physiology ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2 - chemically induced ; Gastrointestinal Diseases - chemically induced ; Gene Expression Regulation - drug effects ; Heart Diseases - chemically induced ; Hematology ; Humans ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukocytosis - chemically induced ; Medicine ; Medicine & Public Health ; Metabolic Networks and Pathways - drug effects ; Methyltransferases - genetics ; Methyltransferases - metabolism ; Neoplasms - chemically induced ; Neoplasms - drug therapy ; Oncology ; Oxides - adverse effects ; Oxides - therapeutic use ; Reactive Oxygen Species - metabolism ; Review Article ; Signal Transduction - drug effects ; Treatment Outcome</subject><ispartof>Annals of hematology, 2013-06, Vol.92 (6), p.719-730</ispartof><rights>Springer-Verlag Berlin Heidelberg 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</citedby><cites>FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-013-1707-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-013-1707-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23494203$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kritharis, Athena</creatorcontrib><creatorcontrib>Bradley, Thomas P.</creatorcontrib><creatorcontrib>Budman, Daniel R.</creatorcontrib><title>The evolving use of arsenic in pharmacotherapy of malignant disease</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><addtitle>Ann Hematol</addtitle><description>For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.</description><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Arsenic Poisoning - diagnosis</subject><subject>Arsenic Poisoning - etiology</subject><subject>Arsenicals - administration & dosage</subject><subject>Arsenicals - adverse effects</subject><subject>Arsenicals - pharmacology</subject><subject>Arsenicals - therapeutic use</subject><subject>Biotransformation - genetics</subject><subject>Biotransformation - physiology</subject><subject>Clinical Trials as Topic</subject><subject>Diabetes Mellitus, Type 2 - chemically induced</subject><subject>Gastrointestinal Diseases - chemically induced</subject><subject>Gene Expression Regulation - drug effects</subject><subject>Heart Diseases - chemically induced</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukocytosis - chemically induced</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic Networks and Pathways - drug effects</subject><subject>Methyltransferases - genetics</subject><subject>Methyltransferases - metabolism</subject><subject>Neoplasms - chemically induced</subject><subject>Neoplasms - drug therapy</subject><subject>Oncology</subject><subject>Oxides - adverse effects</subject><subject>Oxides - therapeutic use</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Review Article</subject><subject>Signal Transduction - drug effects</subject><subject>Treatment Outcome</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kMlOwzAQhi0EoqXwAFxQJM6G8ZLYOaKKTarEpZwtJ560qZoFu6nUt8dVCuLCXOYw_6L5CLll8MAA1GMA4EpRYIIyBYqKMzJlUnAKqZbnZAq5yGkaZ0KuQtgAMK4lvyQTLmQuOYgpmS_XmOC-2-7rdpUMAZOuSqwP2NZlUrdJv7a-sWW3W6O3_eF4bey2XrW23SWuDmgDXpOLym4D3pz2jHy-PC_nb3Tx8fo-f1rQUgq9o6muFGdSVzLFIuNcWFfkZaHzUrmsAGszcOByXoLDQrGKZ1rLVGpbca1QOjEj92Nu77uvAcPObLrBt7HSMJEqpuOnPKrYqCp9F4LHyvS-bqw_GAbmiM2M2EzEZo7YjIieu1PyUDTofh0_nKKAj4IQT-0K_Z_qf1O_AbWLdzE</recordid><startdate>20130601</startdate><enddate>20130601</enddate><creator>Kritharis, Athena</creator><creator>Bradley, Thomas P.</creator><creator>Budman, Daniel R.</creator><general>Springer-Verlag</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20130601</creationdate><title>The evolving use of arsenic in pharmacotherapy of malignant disease</title><author>Kritharis, Athena ; Bradley, Thomas P. ; Budman, Daniel R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-58f72148f45eb6223adb9cb89c7d6b0aa60d0d92c0deb71f26884548af287e4d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Arsenic Poisoning - diagnosis</topic><topic>Arsenic Poisoning - etiology</topic><topic>Arsenicals - administration & dosage</topic><topic>Arsenicals - adverse effects</topic><topic>Arsenicals - pharmacology</topic><topic>Arsenicals - therapeutic use</topic><topic>Biotransformation - genetics</topic><topic>Biotransformation - physiology</topic><topic>Clinical Trials as Topic</topic><topic>Diabetes Mellitus, Type 2 - chemically induced</topic><topic>Gastrointestinal Diseases - chemically induced</topic><topic>Gene Expression Regulation - drug effects</topic><topic>Heart Diseases - chemically induced</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukocytosis - chemically induced</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic Networks and Pathways - drug effects</topic><topic>Methyltransferases - genetics</topic><topic>Methyltransferases - metabolism</topic><topic>Neoplasms - chemically induced</topic><topic>Neoplasms - drug therapy</topic><topic>Oncology</topic><topic>Oxides - adverse effects</topic><topic>Oxides - therapeutic use</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Review Article</topic><topic>Signal Transduction - drug effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kritharis, Athena</creatorcontrib><creatorcontrib>Bradley, Thomas P.</creatorcontrib><creatorcontrib>Budman, Daniel R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kritharis, Athena</au><au>Bradley, Thomas P.</au><au>Budman, Daniel R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The evolving use of arsenic in pharmacotherapy of malignant disease</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><addtitle>Ann Hematol</addtitle><date>2013-06-01</date><risdate>2013</risdate><volume>92</volume><issue>6</issue><spage>719</spage><epage>730</epage><pages>719-730</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>For more than 2,000 years, arsenic and its derivatives have shown medical utility. Owing to the toxicities and potential carcinogenicity of arsenicals, their popularity has fluctuated. The exact mechanism of action of therapeutic arsenic is not well characterized but likely to involve apoptosis, generation of reactive oxygen species, inhibition of intracellular transduction pathways, and cell functions. Arsenic trioxide has received approval for use in patients with relapsed acute promyelocytic leukemia for remission induction. Arsenic has additionally shown activity in a range of solid tumors, myelodysplastic syndrome, multiple myeloma, and in autoimmune diseases. The following is a review of the history of arsenic, its cellular metabolism, pharmacology, genetic basis of disposition, associated toxicities, and clinical efficacy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>23494203</pmid><doi>10.1007/s00277-013-1707-3</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0939-5555 |
ispartof | Annals of hematology, 2013-06, Vol.92 (6), p.719-730 |
issn | 0939-5555 1432-0584 |
language | eng |
recordid | cdi_proquest_journals_1357185552 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Arsenic Poisoning - diagnosis Arsenic Poisoning - etiology Arsenicals - administration & dosage Arsenicals - adverse effects Arsenicals - pharmacology Arsenicals - therapeutic use Biotransformation - genetics Biotransformation - physiology Clinical Trials as Topic Diabetes Mellitus, Type 2 - chemically induced Gastrointestinal Diseases - chemically induced Gene Expression Regulation - drug effects Heart Diseases - chemically induced Hematology Humans Leukemia, Promyelocytic, Acute - drug therapy Leukocytosis - chemically induced Medicine Medicine & Public Health Metabolic Networks and Pathways - drug effects Methyltransferases - genetics Methyltransferases - metabolism Neoplasms - chemically induced Neoplasms - drug therapy Oncology Oxides - adverse effects Oxides - therapeutic use Reactive Oxygen Species - metabolism Review Article Signal Transduction - drug effects Treatment Outcome |
title | The evolving use of arsenic in pharmacotherapy of malignant disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T08%3A49%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20evolving%20use%20of%20arsenic%20in%20pharmacotherapy%20of%20malignant%20disease&rft.jtitle=Annals%20of%20hematology&rft.au=Kritharis,%20Athena&rft.date=2013-06-01&rft.volume=92&rft.issue=6&rft.spage=719&rft.epage=730&rft.pages=719-730&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-013-1707-3&rft_dat=%3Cproquest_cross%3E2984714861%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1357185552&rft_id=info:pmid/23494203&rfr_iscdi=true |